Holtec and Orion180 put $1.2 billion of IPO demand on the calendar

The U.S. IPO calendar returned from Labor Day with two consequential roadshows. Holtec Nuclear set a 50 million-share range of $15 to $18, while Orion180 Insurance Group proposed 20 million shares at $15 to $17. Together, the base deals seek as much as $1.24 billion. The week ended September 13 therefore produced a much cleaner test than another round of placeholder filings: investors now have to price nuclear execution risk, catastrophe-exposed insurance growth and unusually concentrated founder economics.

No conventional IPO in this group completed pricing during the week. The useful change was the arrival of executable terms from two companies with broad underwriting syndicates. Holtec is the larger and more ambitious transaction, and its governance and post-offering economics make the headline valuation only the beginning of the analysis.

Holtec asks investors to fund the next buildout

Holtec launched its roadshow on September 8 with J.P. Morgan, Guggenheim, Goldman Sachs, Citi and BofA leading a nine-bank book. The base offer implies $825 million at the midpoint and $900 million at the top. Reuters calculated an equity valuation of as much as $10.2 billion and placed the deal in a growing run of nuclear offerings tied to rising power demand from data centers and the grid buildout.

The September 8 prospectus shows a real operating platform alongside a capital-intensive development program. Historical revenue was $576.6 million in 2025, down from $765.5 million in 2024, while first-half 2026 revenue was $269.9 million. Net income reached $205.6 million in the first half, but the filing says that result benefited from non-operating asset-retirement-obligation gains and investment income. Operating cash flow was $90.4 million, against $402.8 million of investing cash use.

At the midpoint, Holtec expects about $775.2 million of net proceeds. The public company will use the cash to buy interests in Holtec International, which may then fund general corporate purposes including SMR-300 licensing, deployment and manufacturing capacity. Historical cash was only $27.4 million at June 30, with a $225.3 million working-capital deficit and $1.06 billion of long-term debt including current portions. IPOGrid reads the offer primarily as growth financing for a company whose nuclear ambitions require substantial capital before corresponding cash flows arrive.

The ownership terms deserve equal weight. Class B shares carry ten votes each, and founder-affiliated Holtec Holdings is expected to control about 99% of voting power after the IPO. Holtec International also must make an aggregate $555 million of distributions to founder affiliates before discretionary distributions can reach the public company and other holders. The reviewer’s concern is straightforward: public buyers fund the expansion while receiving little influence over capital allocation. The breadth of the syndicate supports execution, but demand still has to absorb those economics at a premium valuation.

Orion180 pairs rapid growth with pre-IPO cash extraction

Orion180’s amended S-1 targets $320 million at the midpoint and a Nasdaq Global Select listing under OIG. RBC, UBS and Raymond James lead, with Goldman Sachs, Deutsche Bank, Citizens and Texas Capital also on the cover. Gross written premiums increased 68.9% to $443.9 million in 2025, and first-half 2026 operating cash flow rose to $127.7 million from $38.8 million a year earlier.

The financing sequence complicates that growth story. Orion180 paid a $151 million dividend in the first half after drawing on a new credit facility, then borrowed another $49.6 million on September 3 to fund a second dividend. It expects to use offering proceeds to repay $282 million of outstanding debt, with the remainder for general corporate purposes. On midpoint assumptions, debt repayment would consume roughly 88% of gross proceeds before fees.

Our interpretation is that buyers are being asked to recapitalize a fast-growing insurer immediately after existing owners took significant cash out. Property insurance also brings catastrophe exposure and dependence on reinsurance availability and pricing. Orion180 has supplied credible growth and a conventional book, but the aftermarket case will hinge on whether investors assign more weight to underwriting momentum or to the balance-sheet path that precedes the listing.

Hometown adds scale through a different channel

Hometown Financial Group filed a depositor-priority mutual conversion that could rival the week’s roadshows in size. Its S-1 fixes the price at $10 and requires at least 51 million shares to be sold, for a $510 million minimum raise; the adjusted maximum reaches 79.35 million shares. Shares first go to eligible TruNorth Bank depositors, benefit plans and insiders, with any remainder moving to community and potentially syndicated offerings. Nasdaq trading is proposed under HFG.

The proceeds would support the pending Primary Bank acquisition, retire a $135 million senior note, finance an employee-stock-ownership-plan loan and capitalize TruNorth. Hometown reported $6.94 billion of assets and $43.4 million of net income for its latest fiscal year, according to a review of the filing. Nonperforming assets were 1.19% of total assets. We would frame this as a large bank conversion and acquisition-financing event, with completion governed by subscription demand and a minimum-sale condition rather than a standard overnight IPO allocation.

Merger prospectuses did not supply an IPO handoff

Two records that reached late-stage filing form should stay outside the conventional IPO count. Indivior Pharmaceuticals filed a 424B3 merger prospectus for its combination with already-public Supernus. Newcleo’s September 10 communications related to its proposed combination with NewHold Investment Corp. III; the companies say the combined nuclear developer is expected to list as NWCL after closing, as described in their investor-day announcement. Neither filing established fresh underwritten IPO pricing.

The week’s signal is therefore concentrated and measurable. Holtec offers scale, a top-tier book and unusually tight founder control. Orion180 offers strong premium growth alongside an IPO-funded debt reset. Hometown offers a large conversion with its own subscription mechanics. The next verdict comes from final pricing: whether investors demand concessions for governance and pre-offering distributions, or accept the ranges to gain exposure to scarce nuclear and insurance growth stories.